论文部分内容阅读
目的 :研究卡维地洛对缺血再灌注心肌细胞凋亡及bcl 2、bax基因表达的影响 ,探讨卡维地洛抑制缺血再灌注心肌细胞凋亡的可能分子机制。方法 :结扎Wistar大鼠左冠状动脉前降支 (LAD) ,建立大鼠缺血再灌注动物模型。 30只大鼠分 3组 (每组 10只 ) :卡维地洛组 (卡维地洛治疗 )、缺血再灌注组和假手术组。用Tunnel法检测心肌细胞凋亡 ,并用光学显微镜进行细胞计数 ,免疫组化和原位杂交法检测bcl 2、bax基因表达 ,并利用图像分析系统检测二者的平均光密度值 (A值 ) ,进行定量分析。结果 :心肌细胞凋亡数在缺血再灌注组、假手术组和卡维地洛组分别为 36 .8± 9.0、0 .2± 0 .1和 9.5± 3.0 ,各组间差异有统计学意义 (P <0 .0 1)。缺血再灌注组、假手术组和卡维地洛组的bcl 2mRNAA值分别为 0 .0 6± 0 .0 1、0 .0 8± 0 .0 1和 0 .0 9± 0 .0 1,bcl 2蛋白平均A值分别为0 .0 8± 0 .0 2、0 .14± 0 .0 1和 0 .15± 0 .0 3,卡维地洛组与缺血再灌注组相比差异无统计学意义 (P >0 .0 5 ) ;缺血再灌注组bax蛋白的平均A值为 0 .13± 0 .0 2 ,假手术组为 0 .0 7± 0 .0 1,卡维地洛组为 0 .0 6± 0 .0 1,卡维地洛组与缺血再灌注组相比差异有统计学意义 (P <0 .0 5 ) ,bcl 2 /bax蛋白比值在缺血再灌注组、假手术组和卡?
Objective: To investigate the effect of carvedilol on cardiomyocyte apoptosis and the expression of bcl-2 and bax gene in ischemia-reperfusion rats, and to explore the possible molecular mechanism of carvedilol on cardiomyocyte apoptosis during ischemia-reperfusion. Methods: Left anterior descending coronary artery (LAD) was ligated in Wistar rats to establish a rat model of ischemia reperfusion. 30 rats were divided into 3 groups (10 in each group): carvedilol group (carvedilol treatment), ischemia reperfusion group and sham operation group. The apoptosis of cardiomyocytes was detected by Tunnel method. The cell counts, the expression of bcl-2 and bax were detected by immunohistochemistry and in situ hybridization. The average optical density (A value) Quantitative analysis. Results: The number of apoptotic cardiomyocytes in ischemic reperfusion group, sham operation group and carvedilol group were 36.8 ± 9.0,0.2 ± 0 .1 and 9.5 ± 3.0 respectively. The differences among the groups were statistically significant Significance (P <0 .01). The bcl 2 mRNA levels of ischemia-reperfusion group, sham-operated group and carvedilol group were respectively 0.060 ± 0.010.8 ± 0.01 and 0.900 ± 0.100 , the mean A value of bcl 2 protein was 0.08 ± 0.0 2, 0.014 ± 0.01 and 0 .15 ± 0 .0 3, respectively, compared with the ischemia-reperfusion group The difference was not statistically significant (P> 0.05); the average A value of bax protein in ischemia-reperfusion group was 0.13 ± 0.22, and the sham group was 0.70 ± 0.001 There was a significant difference between the carvedilol group and the ischemia-reperfusion group (P <0.05), and the ratio of bcl 2 / bax protein was in the absence Blood reperfusion group, sham operation group and card?